Journal article
Specific Bacteria and Metabolites Associated With Response to Fecal Microbiota Transplantation in Patients With Ulcerative Colitis
S Paramsothy, S Nielsen, MA Kamm, NP Deshpande, JJ Faith, JC Clemente, R Paramsothy, AJ Walsh, J van den Bogaerde, D Samuel, RWL Leong, S Connor, W Ng, E Lin, TJ Borody, MR Wilkins, JF Colombel, HM Mitchell, NO Kaakoush
Gastroenterology | W B SAUNDERS CO-ELSEVIER INC | Published : 2019
Abstract
Background & Aims: Fecal microbiota transplantation (FMT) can induce remission in patients with ulcerative colitis (UC). In a randomized controlled trial of FMT in patients with active UC, we aimed to identify bacterial taxonomic and functional factors associated with response to therapy. Methods: We performed a double-blind trial of 81 patients with active UC randomly assigned to groups that received an initial colonoscopic infusion and then intensive multidonor FMT or placebo enemas, 5 d/wk for 8 weeks. Patients in the FMT group received blended homogenized stool from 3–7 unrelated donors. Patients in the placebo group were eligible to receive open-label FMT after the double-blind study pe..
View full abstractGrants
Awarded by Crohn's and Colitis Foundation of America
Funding Acknowledgements
This study was supported by the Broad Medical Research Program at Crohn's and Colitis Foundation of America (IBD-0391R), the Gastroenterological Society of Australia IBD Clinical Research Grant (2013), Mt Sinai (New York) SUCCESS fund (GCO14-0560), and UNSW Gold Star Award. Sudarshan Paramsothy was supported by a Postgraduate Scholarship from the National Health and Medical Research Council, Australia. Michael A. Kamm is supported by the St Vincent's Research Foundation and the Australasian Gastro Intestinal Research Foundation (AGIRF). Nadeem Omar Kaakoush is supported by a Career Development Fellowship from the Cancer Institute NSW, Australia (15/CDF/1-11). The Centre for Digestive Diseases Research Fund supported the production of the study infusions. Marc R. Wilkins acknowledges funding from Bioplatforms Australia under the Australian Government NCRIS scheme and from the New South Wales State Government's RAAP scheme.